RAPT Therapeutics Inc. (RAPT) is a clinical-stage immunology-based biopharmaceutical company focused on developing novel therapies for the treatment of cancer and inflammatory diseases. The company's lead product candidate, FLX475, is an oral small molecule CCR4 antagonist that is designed to selectively target regulatory T cells (Tregs), which suppress the immune system's ability to attack tumors. By inhibiting Tregs, FLX475 is expected to enhance the anti-tumor activity of other immune cells, such as T cells and natural killer cells. RAPT is also developing other immunotherapy candidates targeting different mechanisms in the immune system, including RPT193 for the treatment of inflammatory bowel disease and other autoimmune disorders. RAPT is headquartered in South San Francisco, California, and as of September 2021, had a market capitalization of approximately $853 million.
RAPT Therapeutics Inc. (RAPT) is a clinical-stage immunology-based biopharmaceutical company focused on developing novel therapies for the treatment of cancer and inflammatory diseases. The company's lead product candidate, FLX475, is an oral small molecule CCR4 antagonist that is designed to selectively target regulatory T cells (Tregs), which suppress the immune system's ability to attack tumors. By inhibiting Tregs, FLX475 is expected to enhance the anti-tumor activity of other immune cells, such as T cells and natural killer cells. RAPT is also developing other immunotherapy candidates targeting different mechanisms in the immune system, including RPT193 for the treatment of inflammatory bowel disease and other autoimmune disorders. RAPT is headquartered in South San Francisco, California, and as of September 2021, had a market capitalization of approximately $853 million.